The clinical use of semaglutide for weight management in the UK

What the trial evidence showed about how semaglutide works in practice

The STEP 1 trial is the clearest window into what semaglutide use looks like in a clinical setting. Over 68 weeks, adults with obesity who received once-weekly semaglutide 2.4 mg alongside lifestyle changes lost an average of around 15% of their body weight, compared with roughly 2.4% in the placebo group. That gap is large enough to carry meaningful clinical weight, reductions in blood pressure, blood sugar and cholesterol risk factors followed alongside the primary weight outcome.

The mechanism is worth understanding plainly. If you want to read about how semaglutide acts on GLP-1 receptors in the brain and gut, our dedicated overview page covers this in full. Appetite signals dampen. Meals feel satisfying sooner. Food moves through the stomach more slowly. None of that is willpower; it is pharmacology working on biology that, for many people, has always pushed against weight loss rather than with it.

Since the original STEP data, the evidence has continued to build. In January 2026, the MHRA issued a Drug Safety Update on GLP-1 medicines, confirming the established risk profile while flagging acute pancreatitis as an infrequent but serious possibility, severe stomach pain extending to the back warrants urgent medical attention. That update is a normal part of how regulators monitor medicines in active use, and it does not change the overall benefit picture established in trials.

A higher maintenance dose of 7.2 mg was approved by the MHRA in April 2026, with trial data suggesting average weight loss approaching 20.7% over 72 weeks. Whether that dose is appropriate depends entirely on a prescriber's assessment of an individual patient.

The dose schedule: what semaglutide use actually looks like week to week

Starting at 0.25 mg, the licensed schedule steps up roughly every four weeks (through 0.5 mg, 1.0 mg and 1.7 mg) before reaching the 2.4 mg maintenance dose. The early doses are primarily about tolerability rather than effect: the most common side effects are gastrointestinal, and a gradual approach gives the body time to adjust. Nausea, loose stools and indigestion are reported most often in the weeks after a dose step, generally settling within a few days to two weeks.

Each injection is subcutaneous: a short, fine needle into the fatty layer beneath the skin at the abdomen, thigh or upper arm. The injection site should be rotated each week. Wegovy pens are stored in the fridge (slipping the week's pen into the fridge door alongside everyday items works for many people, so it becomes part of the routine rather than a separate medical task) though the exact storage window before and after refrigeration is specified in the Patient Information Leaflet and should be followed precisely.

Missed doses, timing adjustments and decisions about continuing at a given dose are all clinical conversations, not things to navigate from a product label. If you are considering semaglutide for weight loss and wondering where the dose steps fit into your situation, that is exactly what a prescriber is there to work through with you. Our guidance on semaglutide 1 mg covers what patients can expect at that particular point in the titration schedule, which many find a useful reference before that step arrives. The NHS patient information on semaglutide covers the standard schedule in straightforward language and is worth reading before any treatment begins.

Who semaglutide use is licensed for, and what the prescriber weighs up

The UK licence for Wegovy covers adults with a BMI of 30 or above, or adults with a BMI of 27 to 29.9 who have at least one weight-related condition, high blood pressure, type 2 diabetes, dyslipidaemia and obstructive sleep apnoea are among those recognised. For some ethnic backgrounds, UK guidance applies lower BMI thresholds, typically 2.5 kg/m² below the standard figures. A BMI figure alone does not determine approval: the prescriber considers the full picture, including current medicines, medical history and any contraindications.

Semaglutide is not recommended during pregnancy, while breastfeeding, or for people trying to conceive. It is not licensed for under-18s. A history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 requires particular care. Women using oral contraceptives should discuss this with their prescriber, as the rate of gastric emptying can affect absorption of other oral medicines taken around the same time, guidance on this sits on the Wegovy overview page.

On the NHS, access to Wegovy is through specialist weight management services under NICE guidance TA875, and waiting lists can be long. Private treatment through a registered online pharmacy is the route for people who do not meet NHS criteria or prefer not to wait. Checking the cost context before committing matters; the Wegovy price comparison page sets out what a legitimate private price covers and what to watch for.

Safety signals worth knowing before use of semaglutide starts

The side-effect profile is dominated by gastrointestinal symptoms, particularly early in treatment: nausea, vomiting, diarrhoea and constipation appear most often, usually mild to moderate and transient. Headache, fatigue and dizziness are also reported. Injection-site reactions are possible. Most people find the GI symptoms ease after the first few weeks at each dose level.

Urgent medical attention is warranted for severe, persistent stomach pain (especially if it radiates to the back, with or without vomiting) as this can signal pancreatitis. Symptoms of a gallbladder problem, signs of dehydration from severe vomiting or diarrhoea, and any allergic reaction also warrant prompt contact with a healthcare professional. Patients can report suspected side effects directly to the MHRA through the Yellow Card scheme.

Semaglutide carries a Black Triangle (▼) designation, meaning it is subject to additional monitoring. That is standard for newer medicines and reflects regulatory diligence rather than unusual concern. Our clinical team reviews every patient's situation before treatment starts and before each repeat, so questions about side-effect management have a clear route, not just a leaflet. Patients sometimes ask about the starting injection volume, and our page on 0.2 ml semaglutide explains what that measurement means in practice and how it relates to the dose. For a broader look at the treatment landscape, the weight management treatment overview sets out the options side by side.

If you would like a prescriber to review whether semaglutide is right for your situation, check your eligibility with a free consultation, reviewed the same working day by a GPhC-registered prescriber, not automated software.